Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991;18(12):973-6.
doi: 10.1007/BF00180418.

Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies

Affiliations

Anomalies in reduction-mediated technetium-99m labelling of monoclonal antibodies

M V Pimm et al. Eur J Nucl Med. 1991.

Abstract

A reduction-mediated technetium-99m labelling method has been evaluated with a range of tumour-specific monoclonal antibodies. Antibodies reduced with 2-mercaptoethanol (2-ME) had free sulphydryl groups, but their number was much higher than could be accounted for by only limited intra-chain reduction of disulphide bonds. Reduced antibody could be labelled efficiently with 99mTc using an methylene diphosphonate (MDP) bone-scanning kit, although this seemed to depend on the presence of residual 2-ME in the preparations. With a carcinoembryonic antigen (CEA)-specific antibody, immunoreactivity of labelled antibody was confirmed, and after injection into nude with CEA-producing xenografts there was localisation into the tumours. Sephacryl S300 gel filtration showed the radiolabel eluting at a single discrete peak at the expected 150 kDa. However, examination of all of the labelled antibodies by polyacrylamide gel electrophoresis (PAGE) and autoradiography showed the presence of a large number of radiolabelled low molecular weight degradation products of the antibodies. These degradation products seemed to be formed in previously reduced antibodies during processing for PAGE, indicating some fragility of the reduced antibody.

PubMed Disclaimer

Similar articles

References

    1. Biotechniques. 1990 May;8(5):512-6 - PubMed
    1. J Immunol Methods. 1991 Mar 21;137(2):217-24 - PubMed
    1. J Nucl Med. 1990 May;31(5):692-7 - PubMed
    1. Eur J Cancer Clin Oncol. 1989 Sep;25(9):1325-32 - PubMed
    1. J Nucl Med. 1986 May;27(5):685-93 - PubMed

Publication types

LinkOut - more resources